Acancer vaccine, oroncovaccine, is avaccine that either treats existingcancer or prevents development of cancer.[1] Vaccines that treat existing cancer are known astherapeutic cancer vaccines ortumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
Some researchers claim that cancerous cells routinely arise and are destroyed by the immune system (immunosurveillance);[2] and that tumors form when the immune system fails to destroy them.[3]
Sometypes of cancer, such ascervical cancer andliver cancer, are caused byviruses (oncoviruses). Traditional vaccines against those viruses, such as theHPV vaccine[4] and thehepatitis B vaccine, prevent those types of cancer. Other cancers are to some extent caused by bacterial infections (e.g.stomach cancer andHelicobacter pylori[5]). Traditional vaccines against cancer-causingbacteria (oncobacteria) are not further discussed in this article.
One approach to cancer vaccination is to separate proteins from cancer cells and immunize patients against those proteins asantigens, in the hope of stimulating the immune system to kill the cancer cells. Research on cancer vaccines is underway for treatment ofbreast,lung,colon,skin,kidney,prostate and other cancers.[6]
Another approach is to generate an immune responsein situ in the patient usingoncolytic viruses. This approach was used in the drugtalimogene laherparepvec, a variant ofherpes simplex virus engineered to selectively replicate in tumor tissue and to express the immune stimulatory proteinGM-CSF. This enhances the anti-tumor immune response totumor antigens released followingviral lysis, creating a patient-specific vaccine.[7]
Tumor antigen vaccines work the same way that viral vaccines work, by training the immune system to attack cells that contain theantigens in the vaccine. The difference is that the antigens for viral vaccines are derived from viruses or cells infected with virus, while the antigens for tumor antigen vaccines are derived from cancer cells. Since tumor antigens are antigens found in cancer cells but not normal cells, vaccinations containing tumor antigens should train the immune system to target cancer cells not healthy cells. Cancer-specific tumor antigens includepeptides from proteins that are not typically found in normal cells but are activated in cancer cells or peptides containing cancer-specific mutations.Antigen-presenting cells (APCs) such asdendritic cells take up antigens from the vaccine, process them intoepitopes, and present the epitopes toT-cells viaMajor Histocompatibility Complex proteins. If T-cells recognize the epitope as foreign, theadaptive immune system is activated and target cells that express the antigens.[8]
Viral vaccines typically work by preventing the spread of the virus. Similarly, cancer vaccines can be designed to target common antigens before cancer evolves if an individual has appropriate risk factors. Additional preventive applications include preventing the cancer from evolving further or undergoingmetastasis and preventing relapse after remission. Therapeutic vaccines focus on killing existing tumors. While cancer vaccines have generally been demonstrated to be safe, their efficacy still needs improvement. One way to potentially improve vaccine therapy is by combining the vaccine with other types of immunotherapy aimed at stimulating the immune system. Since tumors often evolve mechanisms to suppress the immune system,immune checkpoint blockade has recently received a lot of attention as a potential treatment to be combined with vaccines. For therapeutic vaccines, combined therapies can be more aggressive, but greater care to ensure the safety of relatively healthy patients is needed for combinations involving preventive vaccines.[9]
Cancer vaccines can be cell-based, protein- or peptide-based, gene-based (DNA/RNA).[9] or live attenuated bacterial- or viral organisms.[10]
Cell-based vaccines include tumor cells or tumor cell lysates. Tumor cells from the patient are predicted to contain the greatest spectrum of relevant antigens, but this approach is expensive and often requires too many tumor cells from the patient to be effective.[11] Using a combination of established cancer cell lines that resemble the patient's tumor can overcome these barriers, but this approach has yet to be effective. Canvaxin, which incorporates three melanoma cell lines, failed phase III clinical trials.[11] Another cell-based vaccine strategy involves autologousdendritic cells (dendritic cells derived from the patient) to which tumor antigens are added. In this strategy, the antigen-presenting dendritic cells directly stimulate T-cells rather than relying on processing of the antigens by native APCs after the vaccine is delivered. The best known dendritic cell vaccine isSipuleucel-T (Provenge), which only improved survival by four months. The efficacy of dendritic cell vaccines may be limited due to difficulty in getting the cells to migrate tolymph nodes and interact with T-cells.[9]
Peptide-based vaccines usually consist of cancer specific-epitopes and often require anadjuvant (for example,GM-CSF) to stimulate the immune system and enhance antigenicity.[8] Examples of these epitopes includeHer2 peptides, such as GP2 andNeuVax. However, this approach requires MHC profiling of the patient because ofMHC restriction.[12] The need for MHC profile selection can be overcome by using longer peptides ("synthetic long peptides") or purified protein, which are then processed into epitopes by APCs.[12]
Gene-based vaccines are composed of thenucleic acid (DNA/RNA) encoding for the gene. The gene is then expressed in APCs and the resulting protein product is processed into epitopes. Delivery of the gene is particularly challenging for this type of vaccine.[9] At least one drug candidate,mRNA-4157/V940, is investigating newly developedmRNA vaccines for use in this application.[13][14]
Live attenuated, ampicillin-susceptibleListeria monocytogenes strains are part of CRS-207 vaccine.[10]
 | This section needs to beupdated. Please help update this article to reflect recent events or newly available information.(January 2024) |
The clinicaltrials.gov website lists over 1900 trials associated with the term "cancer vaccine". Of these, 186 are Phase 3 trials.[when?]
The following table, summarizing information from another recent review shows an example of the antigen used in the vaccine tested in Phase 1/2 clinical trials for each of 10 different cancers:[11]
| Cancer type | Antigen |
|---|---|
| Bladder cancer | NY-ESO-1 |
| Breast cancer | HER2 |
| Cervical cancer | HPV16 E7 (Papillomaviridae#E7) |
| Colorectal cancer | CEA (Carcinoembryonic antigen) |
| Leukemia | WT1 |
| Melanoma | MART-1,gp100, andtyrosinase |
| Non small lung cell cancer (NSCLC) | URLC10,VEGFR1, andVEGFR2 |
| Ovarian cancer | survivin |
| Pancreatic cancer | MUC1 |
| Prostate cancer | MUC2 |
Oncophage was approved in Russia in 2008 forkidney cancer. It is marketed by Antigenics Inc.[18]
Sipuleucel-T,Provenge, was approved by the FDA in April 2010 for metastatichormone-refractory prostate cancer. It is marketed byDendreon Corp.
CimaVax-EGF was approved in Cuba in 2011.[19] Similar to Oncophage, it is not yet approved for use in the United States, although it is already undergoing phase II trials to that end.[20][21]
Bacillus Calmette-Guérin (BCG) was approved by the FDA in 1990 as a vaccine for early-stage bladder cancer.[22] BCG can be administered intravesically (directly into the bladder) or as anadjuvant in other cancer vaccines.
CancerVax (Canvaxin), Genitope Corp (MyVax personalized immunotherapy), and FavId FavId (Favrille Inc) are examples of cancer vaccine projects that have been terminated, due to poor phase III and IV results.[citation needed]
Cancer vaccines seek to target a tumor-specificantigen as distinct from self-proteins. Selection of the appropriateadjuvant to activate antigen-presenting cells to stimulate immune responses, is required.Bacillus Calmette-Guérin, an aluminum-based salt, and a squalene-oil-water emulsion are approved for clinical use. An effective vaccine should also stimulate long term immune memory to prevent tumor recurrence. Some scientists claim both theinnate andadaptive immune systems must be activated to achieve total tumor elimination.[23]
Tumor antigens have been divided into two categories:shared tumor antigens; andunique tumor antigens. Shared antigens are expressed by many tumors. Unique tumor antigens result from mutations induced through physical or chemical carcinogens; they are therefore expressed only by individual tumors.
In one approach, vaccines contain whole tumor cells, though these vaccines have been less effective in eliciting immune responses in spontaneous cancer models. Defined tumor antigens decrease the risk of autoimmunity, but because the immune response is directed to a singleepitope, tumors can evade destruction through antigen loss variance. A process called "epitope spreading" or "provoked immunity" may mitigate this weakness, as sometimes an immune response to a single antigen can lead to immunity against other antigens on the same tumor.[23]
For example, sinceHsp70 plays an important role in thepresentation of antigens of destroyed cells including cancer cells,[24] this protein may be used as an effective adjuvant in the development of antitumor vaccines.[25]
A vaccine against a particular virus is relatively easy to create. The virus is foreign to the body, and therefore expressesantigens that theimmune system can recognize. Furthermore, viruses usually only provide a few viable variants. By contrast, developing vaccines for viruses that mutate constantly such asinfluenza orHIV has been problematic. A tumor can have many cell types of cells, each with different cell-surface antigens. Those cells are derived from each patient and display few if any antigens that are foreign to that individual. This makes it difficult for the immune system to distinguish cancer cells from normal cells. Some scientists believe thatrenal cancer andmelanoma are the two cancers with most evidence of spontaneous and effective immune responses, possibly because they often display antigens that are evaluated as foreign. Many attempts at developing cancer vaccines are directed against these tumors. However, Provenge's success in prostate cancer, a disease that never spontaneously regresses, suggests that cancers other than melanoma and renal cancer may be equally amenable to immune attack.[citation needed]
However, most vaccine clinical trials have failed or had modest results according to the standardRECIST criteria.[26] The precise reasons are unknown, but possible explanations include:
In January 2009, a review article made recommendations for successful oncovaccine development as follows:[27]
{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)